Life Science News

Applied UV, Inc. (NasdaqCM: AUVI ) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, announced that the Company will be hosting an investor conference call and live webcast on Thursday, April 7, 2022 at 9:00 am ET to review its financial results. Fourth quarter and Year End 2021 financial results will be available through the Investor Relations section of the company's website at https://irdirect.net/AUVI .

Conference Call/Webcast Information

Applied UV's management team will host an investor conference call and live webcast on April 7, 2022, at 9:00 am ET. Investors can access the live webcast via a link on Applied UV's web site at https://www.webcaster4.com/Webcast/Page/2626/44897 . For those planning to participate on the call, please dial +1-877-545-0523 (for domestic calls), or +1-973-528-0016 (for international calls), passcode 651204. A replay of the conference call will be available online on the Applied UV web site, and a dial-in replay will be available for one week following the call at +1-877-481-4010 (for domestic calls) or +1-919-882-2331 (for international calls), replay passcode 44897.

About Applied UV

Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works"). SteriLumen's connected platform for Data Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company's Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices' proximity. The Company's patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen intensive location. SteriLumen's Airocide® air purification devices are research backed, clinically proven, and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photocatalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities and homes. For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/ ; https://sterilumen.com/ ; https://www.airocide.com ; https://kesscience.com ; https://scientificairmanagement.com ; www.airclean420.com , and https://munnworks.com/ .

Forward-Looking Statements

The information contained herein may contain "forward-looking statements." Forward-looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward-looking statements are based on the Company's current expectations and assumptions regarding its business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.

Applied UV, Inc.
Max Munn
Applied UV Interim CEO
max.munn@sterilumen.com

Brett Maas, Managing Principal
Hayden IR
brett@haydenir.com
(646) 536-7331

News Provided by Business Wire via QuoteMedia

AUVI:NSD
Applied UV

Applied UV


Keep reading...Show less

Danaher Reports Second Quarter 2022 Results

Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the second quarter 2022.  All results in this release reflect only continuing operations unless otherwise noted.

For the quarter ended July 1, 2022 , net earnings were $1.7 billion , or $2.25 per diluted common share which represents a 1.5% year-over-year decrease from the comparable 2021 period.  Non-GAAP adjusted diluted net earnings per common share were $2.76 which represents a 12.0% increase over the comparable 2021 period.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Danaher Reports Second Quarter 2022 Results

Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the second quarter 2022.  All results in this release reflect only continuing operations unless otherwise noted.

For the quarter ended July 1, 2022 , net earnings were $1.7 billion , or $2.25 per diluted common share which represents a 1.5% year-over-year decrease from the comparable 2021 period.  Non-GAAP adjusted diluted net earnings per common share were $2.76 which represents a 12.0% increase over the comparable 2021 period.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Danaher Reports Second Quarter 2022 Results

Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the second quarter 2022.  All results in this release reflect only continuing operations unless otherwise noted.

For the quarter ended July 1, 2022 , net earnings were $1.7 billion , or $2.25 per diluted common share which represents a 1.5% year-over-year decrease from the comparable 2021 period.  Non-GAAP adjusted diluted net earnings per common share were $2.76 which represents a 12.0% increase over the comparable 2021 period.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Abbott Reports Second-Quarter 2022 Results and Raises Full-Year EPS Guidance

  • Sales growth of 10.1 percent; organic sales growth of 14.3 percent
  • GAAP diluted EPS growth of 72.7 percent; adjusted diluted EPS growth of 22.2 percent
  • Global COVID-19 testing-related sales of $2.3 billion in the second quarter
  • Continues to strengthen portfolio with new product approvals

Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2022 .

  • Second-quarter sales of $11.3 billion increased 10.1 percent on a reported basis and 14.3 percent on an organic basis, which excludes the impact of foreign exchange.
  • GAAP diluted EPS 1 was $1.14 in the second quarter. Excluding specified items, adjusted diluted EPS was $1.43 , which reflects growth of 22.2 percent compared to the prior year.
  • Global COVID-19 testing-related sales were $2.3 billion in the second quarter.
  • Abbott is raising its full-year 2022 EPS guidance. Abbott projects full-year diluted EPS on a GAAP basis of at least $3.50 and projected adjusted diluted EPS of at least $4.90 .
  • 2022 guidance includes projected COVID-19 testing-related sales of $6.1 billion , which includes sales of $5.6 billion through June 2022 and projected sales of $500 million over the next few months.
  • In April, Abbott announced U.S. Food and Drug Administration (FDA) approval of its Aveir™ single-chamber (VR) leadless pacemaker for the treatment of patients with slow heart rhythms. Aveir VR is the world's only leadless pacemaker with a unique mapping capability to assess correct positioning prior to placement and was specifically designed to be expandable and retrievable when therapy needs evolve or the device needs to be replaced.
  • In May, Abbott announced U.S. FDA clearance of its FreeStyle Libre ® 3 system, which automatically delivers up-to-the-minute glucose readings and unsurpassed 14-day accuracy 2 in the world's smallest and thinnest 3 wearable sensor.
  • In June, Abbott announced breakthrough device designation from the U.S. FDA for its first-of-its-kind glucose-ketone biowearable sensor development program, which will enable people with diabetes to continuously monitor glucose and ketones in one sensor, helping those at risk for developing a life-threatening complication called diabetic ketoacidosis.

"We achieved another quarter of strong growth and are raising our full-year EPS guidance," said Robert B. Ford , chairman and chief executive officer, Abbott. "Our new product pipeline has remained highly productive, and our diversified business has continued to be resilient in a challenging macro environment."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Abbott Reports Second-Quarter 2022 Results and Raises Full-Year EPS Guidance

  • Sales growth of 10.1 percent; organic sales growth of 14.3 percent
  • GAAP diluted EPS growth of 72.7 percent; adjusted diluted EPS growth of 22.2 percent
  • Global COVID-19 testing-related sales of $2.3 billion in the second quarter
  • Continues to strengthen portfolio with new product approvals

Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2022 .

  • Second-quarter sales of $11.3 billion increased 10.1 percent on a reported basis and 14.3 percent on an organic basis, which excludes the impact of foreign exchange.
  • GAAP diluted EPS 1 was $1.14 in the second quarter. Excluding specified items, adjusted diluted EPS was $1.43 , which reflects growth of 22.2 percent compared to the prior year.
  • Global COVID-19 testing-related sales were $2.3 billion in the second quarter.
  • Abbott is raising its full-year 2022 EPS guidance. Abbott projects full-year diluted EPS on a GAAP basis of at least $3.50 and projected adjusted diluted EPS of at least $4.90 .
  • 2022 guidance includes projected COVID-19 testing-related sales of $6.1 billion , which includes sales of $5.6 billion through June 2022 and projected sales of $500 million over the next few months.
  • In April, Abbott announced U.S. Food and Drug Administration (FDA) approval of its Aveir™ single-chamber (VR) leadless pacemaker for the treatment of patients with slow heart rhythms. Aveir VR is the world's only leadless pacemaker with a unique mapping capability to assess correct positioning prior to placement and was specifically designed to be expandable and retrievable when therapy needs evolve or the device needs to be replaced.
  • In May, Abbott announced U.S. FDA clearance of its FreeStyle Libre ® 3 system, which automatically delivers up-to-the-minute glucose readings and unsurpassed 14-day accuracy 2 in the world's smallest and thinnest 3 wearable sensor.
  • In June, Abbott announced breakthrough device designation from the U.S. FDA for its first-of-its-kind glucose-ketone biowearable sensor development program, which will enable people with diabetes to continuously monitor glucose and ketones in one sensor, helping those at risk for developing a life-threatening complication called diabetic ketoacidosis.

"We achieved another quarter of strong growth and are raising our full-year EPS guidance," said Robert B. Ford , chairman and chief executive officer, Abbott. "Our new product pipeline has remained highly productive, and our diversified business has continued to be resilient in a challenging macro environment."

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Abbott Reports Second-Quarter 2022 Results and Raises Full-Year EPS Guidance

  • Sales growth of 10.1 percent; organic sales growth of 14.3 percent
  • GAAP diluted EPS growth of 72.7 percent; adjusted diluted EPS growth of 22.2 percent
  • Global COVID-19 testing-related sales of $2.3 billion in the second quarter
  • Continues to strengthen portfolio with new product approvals

Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2022 .

  • Second-quarter sales of $11.3 billion increased 10.1 percent on a reported basis and 14.3 percent on an organic basis, which excludes the impact of foreign exchange.
  • GAAP diluted EPS 1 was $1.14 in the second quarter. Excluding specified items, adjusted diluted EPS was $1.43 , which reflects growth of 22.2 percent compared to the prior year.
  • Global COVID-19 testing-related sales were $2.3 billion in the second quarter.
  • Abbott is raising its full-year 2022 EPS guidance. Abbott projects full-year diluted EPS on a GAAP basis of at least $3.50 and projected adjusted diluted EPS of at least $4.90 .
  • 2022 guidance includes projected COVID-19 testing-related sales of $6.1 billion , which includes sales of $5.6 billion through June 2022 and projected sales of $500 million over the next few months.
  • In April, Abbott announced U.S. Food and Drug Administration (FDA) approval of its Aveir™ single-chamber (VR) leadless pacemaker for the treatment of patients with slow heart rhythms. Aveir VR is the world's only leadless pacemaker with a unique mapping capability to assess correct positioning prior to placement and was specifically designed to be expandable and retrievable when therapy needs evolve or the device needs to be replaced.
  • In May, Abbott announced U.S. FDA clearance of its FreeStyle Libre ® 3 system, which automatically delivers up-to-the-minute glucose readings and unsurpassed 14-day accuracy 2 in the world's smallest and thinnest 3 wearable sensor.
  • In June, Abbott announced breakthrough device designation from the U.S. FDA for its first-of-its-kind glucose-ketone biowearable sensor development program, which will enable people with diabetes to continuously monitor glucose and ketones in one sensor, helping those at risk for developing a life-threatening complication called diabetic ketoacidosis.

"We achieved another quarter of strong growth and are raising our full-year EPS guidance," said Robert B. Ford , chairman and chief executive officer, Abbott. "Our new product pipeline has remained highly productive, and our diversified business has continued to be resilient in a challenging macro environment."